Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, February 17, 2022
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
[ Thu, Feb 17th 2022
] - WOPRAI
Wed, February 16, 2022
[ Wed, Feb 16th 2022
] - WOPRAI
John Newman Maintained (AGIO) at Strong Buy with Decreased Target to $44 on, Feb 16th, 2022
John Newman of Canaccord Genuity, Maintained "Agios Pharmaceuticals, Inc." (AGIO) at Strong Buy with Decreased Target from $52 to $44 on, Feb 16th, 2022.
John has made no other calls on AGIO in the last 4 months.
There are 3 other peers that have a rating on AGIO. Out of the 3 peers that are also analyzing AGIO, 1 agrees with John's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Andrew Berens of "SVB Leerink" Maintained at Hold with Decreased Target to $42 on, Thursday, November 18th, 2021
These are the ratings of the 2 analyists that currently disagree with John
- Greg Harrison of "B of A Securities" Initiated at Strong Buy and Held Target at $54 on, Friday, December 3rd, 2021
- Michael King of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $95 on, Thursday, November 4th, 2021
